Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seagren, S.
Right arrow Articles by Horn, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Seagren, S.
Right arrow Articles by Horn, R.

Chest, Vol 88, 810-814, Copyright © 1985 by American College of Chest Physicians

ARTICLES

High dose rate intraluminal irradiation in recurrent endobronchial carcinoma

SL Seagren, JH Harrell and RA Horn

Palliative therapy for previously irradiated patients with symptomatic recurrent endobronchial malignancy is a difficult problem. We have had the opportunity to treat 20 such patients with high dose rate (50-100 rad/min) endobronchial brachytherapy. Eligible patients had received previous high dose thoracic irradiation (TDF greater than or equal to 90), a performance status of greater than or equal to 50, and symptoms caused by a bronchoscopically defined and implantable lesion. The radiation is produced by a small cobalt-60 source (0.7 Ci) remotely afterloaded by cable control. The source is fed into a 4 mm diameter catheter which is placed with bronchoscopic guidance; it may oscillate if necessary to cover the lesion. A dose of 1,000 rad at 1 cm from the source is delivered. We have performed 22 procedures in 20 patients, four following YAG laser debulking. Most had cough, some with hemoptysis. Eight had dyspnea secondary to obstruction and three had obstructive pneumonitis. In 12, symptoms recurred with a mean time to recurrence of 4.3 months (range 1-9 months). Eighteen patients were followed-up and reexamined via bronchoscope 1-2.5 months following the procedure; two were lost to follow-up. All had at least 50 percent clearance of tumor, and six had complete clearance; most regressions were documented on film or videotape. In six, the palliation was durable. The procedure has been well tolerated with no toxicity. We conclude that palliative endobronchial high dose rate brachytherapy is a useful palliative modality in patients with recurrent endobronchial symptomatic carcinoma.


This article has been cited by other articles:


Home page
 ChestHome page
P. A. Kvale, M. Simoff, and U. B. S. Prakash
Palliative Care
Chest, January 1, 2003; 123(1_suppl): 284S - 311S.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. M. Seijo and D. H. Sterman
Interventional Pulmonology
N. Engl. J. Med., March 8, 2001; 344(10): 740 - 749.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. R. Sonett, R. J. Keenan, P. F. Ferson, B. P. Griffith, and R. J. Landreneau
Endobronchial Management of Benign, Malignant, and Lung Transplantation Airway Stenoses
Ann. Thorac. Surg., June 1, 1995; 59(6): 1417 - 1422.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American College of Chest Physicians.